Portola Pharmaceuticals, Inc.

Millennium Pharmaceuticals Limited

Myokardia, Inc.

Conjuchem, Inc.

Cor Therapeutics, Inc.

Alexion Pharmaceuticals, Inc.

Redcell Canada, Inc.

Millennium Pahrmaceuticals, Inc.

Yonghong Song

Anjali Pandey

Zhaozhong Jon Jia

Qing Xu

Robert M Scarborough

Shawn M Bauer

Bing-Yan Zhu

Brian Kane

Mukund Mehrotra

Wenrong Huang

Jack W Rose

Wolin Huang

Penglie Zhang

Erick A Goldman

Lingyan Wang

Wenhao Li

Jingmei Zuckett

Chandrasekar Venkataramani

Robert S McDowell

Johan D Oslob

Danielle Aubele

Arvinder Sran

Marc Evanchik

Jonathan Charles Fox

Robert G Anderson

Min Zhong

Alexander Krantz

Hector Rodriguez

Alan M Ezrin

James P Kanter

Ting Su

Puping Lu

Jae Kim

Shumei Wang

Carroll Scarborough, Legal Representative

Lane Clizbe

Willy Teng

Robert Mcdowell

Charles K Marlowe

Gary D Probst

Kim A Kane-Maguire

Yanchen Zhang

Mark Grillo

Dominique Blanchard

Carroll Anna Crew Scarborough, Legal Representative

Diane DeNagel

Pu-Ping Lu

Brandon Doughan

Chhaya Bhakta

Jack Rose

Robert Anderson

Johan Oslob

Provided are novel pyrimidine dione compounds and pharmaceutically acceptable salts thereof, that are useful for the treatment of hypertrophic cardiomyopathy (HCM) and conditions associated with left ventricular hypertrophy or diastolic dysfunction. The synthesis and characterization of the compounds and pharmaceutically acceptable salts thereof, are described, as well as methods for treating HCM and other forms of heart disease.

Pyrimidinedione compounds

The present invention is directed to methods of treating multiple myeloma by administering a compound of Formula (I) or pharmaceutically acceptable salt thereof.

Inhibitors of protein kinases

The present invention provides novel 4-methylsulphone-substituted piperidine urea compounds that are useful for the treatment of dilated cardiomyopathy (DCM) and conditions associated with left and/or right ventricular systolic dysfunction or systolic reserve. The synthesis and characterization of the compounds is described, as well as methods for treating DCM and other forms of heart disease.

4-methylsulfonyl-substituted piperidine urea compounds

The present invention is directed to topical pharmaceutical compositions of Formula (If) or pharmaceutically acceptable salt thereof, which act as inhibitors of syk and/or JAK kinase activity. The described topical pharmaceutical compositions are useful in preventing or treating a number of conditions mediated at least in part by syk and/or JAK kinase activity.

The present invention is directed to compounds of formula I and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of Syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition Syk kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by Syk kinase activity, such as Non Hodgkin's Lymphoma.

Benzamides and nicotinamides as Syk modulators

In one aspect, the invention provides a compound according to formula I, as well as tautomers, pharmaceutically acceptable salts, and hydrates thereof. Pharmaceutical compositions, methods of inhibiting Janus kinases (JAKs), and methods for treating a condition or disorder mediated at least in part by JAK kinase activity are also described. 

Pyridazine compounds as JAK inhibitors

Provided are substituted pyrimidinyl compounds for inhibition of JAK and/or Syk kinase, pharmaceutical compositions thereof, methods for inhibiting JAK and/or Syk kinase activity, and methods for treating conditions mediated at least in part by JAK and/or Syk kinase activity.

Substituted pyrimidinyl kinase inhibitors

The present invention provides novel bicyclic pyrimidinedione compounds that are useful for the treatment of hypertrophic cardiomyopathy (HCM) and conditions associated with left ventricular hypertrophy or diastolic dysfunction. The synthesis and characterization of the compounds is described, as well as methods for treating HCM and other forms of heart disease.

Bicyclic-pyrimidinedione compounds

The present invention is directed to compounds of formula I-V and tautomers thereof or pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.

Inhibitors of syk and JAK protein kinases

Provided are bicyclic dihydropyridone compounds for inhibiting of JAK/Syk kinase, intermediates used in making such compounds, methods for their preparation, pharmaceutical compositions thereof, methods for inhibiting JAK/Syk kinase activity, and methods for treating conditions mediated at least in part by JAK/Syk kinase activity.

Bicyclic dihydropyridone kinase inhibitors

Provided are bicyclic oxa-lactam compounds of formula I: and pharmaceutically acceptable salts thereof which are inhibitors of JAK/Syk kinase. The present disclosure is also directed to intermediates used in making such compounds, methods for their preparation, pharmaceutical compositions thereof, methods for inhibiting JAK/Syk kinase activity, and methods for treating conditions mediated at least in part by JAK/Syk kinase activity.

Bicyclic oxa-lactam kinase inhibitors

Growing community of inventors

Foster City, CA, United States of America

Yonghong Song